Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

NxStage Medical Inc gives Q2 2014 guidance in line with analysts' estimates; Sees FY 2014 revenue guidance at high end of prior range


Thursday, 8 May 2014 07:23am EDT 

NxStage Medical Inc gives:Believes the company is trending towards the higher end of FY 2014 revenue guidance which was originally set to be between $283 million and $288 million.Expects Q2 2014 revenue to be between $70.0 million and $71.5 million.Expects Q2 2014 net loss in the range of $7.5 million to $6.5 million.Q2 2014 revenue of $70.5 million and net income of $(6.5) million - Thomson Reuters I/B/E/S.FY 2014 revenue of $287 million - Thomson Reuters I/B/E/S. 

Company Quote

18.19
-0.2 -1.09%
26 Dec 2014